Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential
作者： Michael Soyka
DOI: 10.1517/14656566.2016.1146689
关键词: Psychiatry 、 Psychosocial 、 Naltrexone 、 Alcohol 、 Antagonist 、 Medicine 、 Nalmefene 、 Harm reduction 、 Agonist 、 Opioid antagonist
摘要: ABSTRACTIntroduction: Few pharmacotherapies are available for alcoholism. Numerous studies indicate the involvement of opioid-endorphin system in mediating reinforcing effects alcohol via dopaminergic neurons. The opioid antagonist naltrexone was found to be effective treatment, and European Medicines Agency has now approved mu-opioid und partial kappa agonist nalmefene.Areas covered: This article presents background information on chemistry nalmefene pre-clinical clinical findings. three relevant Phase III studies, all which followed a harm-reduction, “as needed” approach reduced consumption with 18 (20) mg, discussed detail.Expert opinion: integration into conventional psychosocial therapies may challenging but offers opportunity reach otherwise not treated patients. Nalmefene is first medication specifically this indication seems t...
sci-hub.se 参考文章(100)
Sten Thelander, Mats Berglund, Egon Jonsson, Treating alcohol and drug abuse : an evidence based review John Wiley. ,(2003)
Bolger G, Weissman Ba, Michel Me, Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods and Findings in Experimental and Clinical Pharmacology. ,vol. 7, pp. 175- 177 ,(1985)
Alain Braillon, Bernard Granger, Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing? Substance Abuse and Rehabilitation. ,vol. 6, pp. 75- 80 ,(2015) , 10.2147/SAR.S86007
Jennifer K. Penberthy, Joshua N. Hook, Michelle D. Vaughan, Don E. Davis, James N. Wagley, Carlo C. DiClemente, Bankole A. Johnson, Impact of motivational changes on drinking outcomes in pharmacobehavioral treatment for alcohol dependence. Alcoholism: Clinical and Experimental Research. ,vol. 35, pp. 1694- 1704 ,(2011) , 10.1111/J.1530-0277.2011.01516.X
Rainer Spanagel, Valentina Vengeliene, New Pharmacological Treatment Strategies for Relapse Prevention Current topics in behavioral neurosciences. ,vol. 13, pp. 583- 609 ,(2012) , 10.1007/7854_2012_205
Kim Donoghue, Catherine Elzerbi, Rob Saunders, Craig Whittington, Stephen Pilling, Colin Drummond, The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. ,vol. 110, pp. 920- 930 ,(2015) , 10.1111/ADD.12875
Clément François, Nora Rahhali, Ylana Chalem, Per Sørensen, Amandine Luquiens, Henri-Jean Aubin, The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients. PLOS ONE. ,vol. 10, ,(2015) , 10.1371/JOURNAL.PONE.0129289
Antonio‐Javier Chamorro, Miguel Marcos, José‐Antonio Mirón‐Canelo, Isabel Pastor, Rogelio González‐Sarmiento, Francisco‐Javier Laso, None, Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis Addiction Biology. ,vol. 17, pp. 505- 512 ,(2012) , 10.1111/J.1369-1600.2012.00442.X
Sanjiv V. Bhave, Peter Clapp, Paula L. Hoffman, How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective. Alcohol Research & Health. ,vol. 31, pp. 310- 339 ,(2008)
Karl Björk, Anton Terasmaa, Hui Sun, Annika Thorsell, Wolfgang H. Sommer, Markus Heilig, Ethanol-induced activation of AKT and DARPP-32 in the mouse striatum mediated by opioid receptors. Addiction Biology. ,vol. 15, pp. 299- 303 ,(2010) , 10.1111/J.1369-1600.2010.00212.X